Latest News

Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth

CANTON, Mich. (2/7/2023) – MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer. This comes as the company was recognized in the 2023 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates, and a Great Place to Work in India.

Schoonmaker have decades of experience in the pharmaceutical and healthcare industry and have held leadership positions at other CROs.

“We are excited to welcome Chris to the #OneMMS team,” said Dr. Uma Sharma, Chief Executive Officer, MMS. “I look forward to his leadership and strength for our continued growth as we scale our teams and clients globally to be the best in business.”

MMS Growth

The expansion of the MMS executive leadership team, will allow the company to continue growing its teams and services across its global operations.

We have strong expertise across our many services, and I look forward to connecting Sponsors with the MMS services that are the right fit for their needs.

Enhancing the MMS Mission

MMS has maintained one of the highest retention rates in the pharma industry and a positive colleague culture since its inception. These aspects of MMS enhance its mission of delivering high-quality service and technology solutions to assist clients in developing life-changing therapies.

Recently, MMS was recognized for its great company culture by the Top Workplaces USA awards for the second consecutive year. The winners of this award are chosen based solely on employee feedback gathered through an employee engagement survey.

“I’m grateful to work at a company with such a strong company culture that cares about its colleagues,” said Schoonmaker, COO, MMS. “Being a part of growing the company and developing the business strategies and operational excellence needed to continue our success is exciting and rewarding to me after many years in this space.”

About MMS

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.

Media Contact
Prasad Babu
media@mmsholdings.com

Suggested For You

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization

news

April 4th, 2024

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

news

March 6th, 2024

MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

news

December 13th, 2023

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

news

April 18th, 2023

MMS Named Great Place to Work in the UK as Growth in the Region Doubles

news

March 21st, 2023

MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

news

February 21st, 2023

MMS Partners with I-ACT to Advance Children’s Clinical Trials

news

January 11th, 2023

MMS Named a Great Place to Work in India